A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®

Condition(s) targeted: Asthma

Phase: Phase 4

Status: Completed

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
Zhou Xin, Principal Investigator, Affiliation: Shanghai First People's Hospital
Hong Jianguo, Principal Investigator, Affiliation: Shanghai First People's Hospital

The purpose of this study is to investigate real practices of treatment with Symbicort Turbuhaler for 3 months in asthma and patient compliance.

Official title: A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®

Study design: Cohort, Prospective

Minimum age: 6 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

1. Provision of informed consent

2. Asthmatics who has been prescribed Symbicort according to physician's judgement

3. Usage of Symbicort should follow local prescribing information

Exclusion Criteria:

1. Not being involved in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)

2. No previous enrolment in the present study

Research Site, Shanghai, China

Research Site, Chongqing, China

Research Site, Beijing, China

Research Site, Hangzhou, China

Research Site, Hefel, Anhui, China

Research Site, Fuzhou, Fujian, China

Research Site, Guangzhou, Guangdong, China

Research Site, Shenzhen, Guangdong, China

Research Site, Zhengzhou, Henan, China

Research Site, Wuhan, Hubei, China

Research Site, Wuhan, Hubel, China

Research Site, Suzhou, Jiangsu, China

Research Site, Nanjong, Jiangsu, China

Research Site, Shenyand, Liaoning, China

Research Site, Qingdao, Shandong, China

Research Site, Xi'an, Shanxi, China

Research Site, Taiyuan, Shanxi, China

Research Site, Chengdu, Sichuan, China

Research Site, Wenzhou, Zhejiang, China

Starting date: April 2007
Ending date: December 2007
Last updated: May 21, 2008